Yes, African Americans are at dramatically increased risk for CKD and end-stage renal disease
African Americans face 3 to 5 times greater risk of end-stage renal disease (ESRD) compared to White Americans, despite having similar overall CKD prevalence rates. 1 This represents one of the most striking racial health disparities in nephrology.
Key Racial/Ethnic Risk Groups
African Americans (Highest Risk)
- CKD prevalence: 11.2% (similar to Whites at 11.6%) 1
- ESRD risk: 3-5 times higher than White Americans 1
- Progression risk: Among those with diabetes, 56% higher risk of developing ESRD even after adjusting for age, sex, BMI, smoking, and comorbidities 2
- Faster decline: 0.31 ml/min per 1.73 m²/yr faster kidney function decline compared to Whites 3
Biological mechanism: The APOL1 gene variants (G1 and G2), present in approximately 13% of African Americans, confer a 7-fold increased risk for ESRD and 10-29 fold increased risk for focal segmental glomerulosclerosis (FSGS) 4. These variants arose as protection against trypanosomiasis in West Africa but now predispose to kidney disease 4, 5.
Hispanic Americans (Variable Risk)
- Overall CKD prevalence: Similar to other groups
- Critical distinction: Risk varies dramatically by ancestry origin 6
- APOL1 factor: Hispanics of Caribbean background (2% prevalence of high-risk genotypes) share similar genetic risk as African Americans 4
Native Americans
- ESRD risk: Nearly 2 times greater than Whites 7
- Identified as high-risk population requiring targeted screening 8
Asian Americans and Pacific Islanders
- Heterogeneous risk: Aggregating these groups masks important differences 9
- Native Hawaiian and Pacific Islanders: Higher risk of microalbuminuria (OR 2.48) and macroalbuminuria compared to Whites 9
- Chinese Americans: Higher risk of microalbuminuria (OR 2.37) but similar kidney function decline rates to Whites 9, 3
- Overall: Lower control rates for hypertension (39.9% in Asian Americans vs 53.8% in Whites) 6
Clinical Implications
Screening Recommendations
Screen aggressively in these high-risk racial/ethnic groups 10:
- African Americans (all adults with hypertension, diabetes, or cardiovascular disease)
- Native Americans
- Hispanics of Caribbean origin
- Native Hawaiian and Pacific Islanders
Treatment Considerations
For African Americans with hypertension (without heart failure or CKD):
- Start with thiazide-type diuretic or calcium channel blocker (not ACE inhibitor/ARB as monotherapy) 6
- These agents are more effective for BP control in Black patients
- Two or more medications typically needed to achieve BP <130/80 mmHg 6
Important Caveats
APOL1 testing limitations: Not recommended for routine screening because only 20% of high-risk genotype carriers develop CKD, and no specific preventive therapy exists yet 4
Socioeconomic confounding: Much of the disparity relates to barriers including lower socioeconomic status, discrimination, healthcare access, and environmental factors 2, 11
Don't aggregate Asian populations: Treating "Asian Americans" as monolithic masks critical differences between East Asian, South Asian, and Pacific Islander subgroups 9
Hispanic heterogeneity matters: Always consider ancestry origin when assessing risk in Hispanic patients 6, 3
The evidence unequivocally demonstrates that race/ethnicity significantly impacts CKD risk, with African Americans bearing the highest burden of progression to ESRD. However, these disparities reflect complex interactions of genetic susceptibility (particularly APOL1), biological factors (preterm birth rates, comorbidity burden), and profound socioeconomic barriers to care 1, 2.